Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Avacopan has demonstrated effectiveness in managing the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), by helping maintain remission while allowing glucocorticoid (GC) tapering. It has shown better sustained remission at 12 months compared to high-dose GCs, contributing to improved renal function and quality of life.
• Comparatively, avacopan can be combined with rituximab or cyclophosphamide to reduce GC exposure while maintaining efficacy in remission induction. Its ability to reduce GC-related adverse effects is particularly beneficial in subgroups with severe or organ-threatening disease and the geriatric population.
• Avacopan has a safer profile compared to high-dose glucocorticoids in treating ANCA-associated vasculitis, with fewer serious adverse events and a reduced risk of serious infections when GC tapering is accelerated.
• In elderly patients, avacopan significantly reduces GC-related complications, such as cardiovascular diseases, infections, and malignancies, making it particularly beneficial for this vulnerable population.
• The population most commonly affected by ANCA-associated vasculitis includes the geriatric population, who face challenges related to glucocorticoid-related adverse effects such as cardiovascular disease, infections, and malignancies. In these patients, avacopan is considered beneficial for reducing these risks while managing the disease, particularly in cases of life-threatening or organ-threatening AAV.